Prescribing Information
About Trelstar
Understanding Prostate Cancer
Information For Healthcare Professionals
  About TRELSTAR
  Administering TRELSTAR
  Oder TRELSTAR
  Reimbursement & Support Programs
  Request Additional Information
  Additional Resources
  TRELSTAR Events/CME
  Prescribing Information
Order TRELSTAR
Additional Resources
This section lists selected voluntary, government, and private organizations that offer educational materials and other services to healthcare providers and patients.

This information is offered as a resource to the users of TRELSTAR.com. The organizations listed are not necessarily endorsed by TRELSTAR.com.

  » American Association for Cancer Research
  » American Institute for Cancer Research
  » American Society of Clinical Oncology
  » American Prostate Society
  » American Urological Association
  » Center for Prostate Disease Research
  » Cancer Care
  » Cancer Hope Network
  » Cancer Research Institute
  » National Cancer Institute
  » National Prostate Cancer Coalition
  » National Coalition for Cancer Survivorship
  » National Comprehensive Cancer Network
  » Prostate Pointers
  » Prostate Cancer Education Council
  » Prostate Forum
  » Prostate Cancer Research Institute
  » Us Too
     
   
Indications and Usage
TRELSTAR® Depot and TRELSTAR® LA are indicated in the palliative treatment of advanced prostate cancer. TRELSTAR Depot and TRELSTAR LA offer an alternative treatment for prostate cancer when orchiectomy or estrogen administration are either not indicated or unacceptable to the patient.
 
Safety Information
The most commonly reported adverse events associated with the use of TRELSTAR Depot/TRELSTAR LA included hot flushes (58.6%/73.0%), skeletal pain (12.1%/13.2%), impotence (7.1%/2.3%), headache (5.0%/6.9%), leg pain (2.1%/5.2%), and edema in legs (0.0%/6.3%) . TRELSTAR is contraindicated in women who are or may become pregnant as well as patients who are hypersensitive to triptorelin, other LHRH agonists, or LHRH . Infrequent postmarketing reports of anaphylactic shock and angioedema have been received since 1986 (global experience) . As with all LHRH agonists, triptorelin causes an initial transient increase in testosterone levels. Patients may experience the onset or exacerbation of symptoms during this period, including bone pain, neuropathy, hematuria, spinal cord compression, or urethral or bladder outlet obstruction. Patients with metastatic vertebral lesions and/or urinary tract obstruction should be closely observed.